MARKET

RARE

RARE

Ultragenyx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

81.30
+2.01
+2.54%
After Hours: 81.30 0 0.00% 16:46 07/28 EDT
OPEN
79.55
PREV CLOSE
79.29
HIGH
81.88
LOW
79.54
VOLUME
334.62K
TURNOVER
--
52 WEEK HIGH
179.65
52 WEEK LOW
72.83
MARKET CAP
5.49B
P/E (TTM)
-26.0544
1D
5D
1M
3M
1Y
5Y
Ultragenyx to Host Conference Call for Second Quarter 2021 Financial Results and Corporate Update
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel therapies for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Monday, August 2, 2021 at 5pm ...
GlobeNewswire · 23h ago
BRIEF-Ultragenyx Receives Orphan Drug Designation From FDA And European Commission For Ux053, An Investigational Mrna-Therapy For The Treatment Of Glycogen Storage Disease Type Iii
reuters.com · 1d ago
Ultragenyx's UX053 gets FDA and EC Orphan Drug status'
libre de droit/iStock via Getty Images Ultragenyx Pharmaceutical (RARE) announces that the U.S. FDA and the European Commission ((EC)) have granted Orphan Drug Designation for UX053 for the treatment of Glycogen
Seekingalpha · 1d ago
Ultragenyx Receives Orphan Drug Designation from FDA and European Commission for UX053, an Investigational mRNA-therapy for the Treatment of Glycogen Storage Disease Type III
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that the U.S.
Benzinga · 1d ago
Ultragenyx Gets FDA, EC Orphan Designation for UX053 in Metabolic Disease >RARE
marketwatch.com · 1d ago
Ultragenyx Pharmaceutical's UX053 Granted Orphan Drug Designation in US, EU
MT Newswires · 1d ago
Earnings Preview: Ultragenyx (RARE) Q2 Earnings Expected to Decline
Zacks.com · 6d ago
Guggenheim Initiates Ultragenyx Pharmaceutical at Neutral
MT Newswires · 07/15 08:47
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RARE. Analyze the recent business situations of Ultragenyx through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 17 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RARE stock price target is 153.50 with a high estimate of 195.00 and a low estimate of 99.00.
EPS
Institutional Holdings
Institutions: 330
Institutional Holdings: 74.07M
% Owned: 109.76%
Shares Outstanding: 67.48M
TypeInstitutionsShares
Increased
85
3.29M
New
42
919.57K
Decreased
96
3.50M
Sold Out
35
232.53K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.51%
Pharmaceuticals & Medical Research
+1.83%
Key Executives
Non-Executive Chairman/Independent Director
Daniel Welch
President/Chief Executive Officer/Director
Emil Kakkis
Chief Financial Officer/Executive Vice President
Mardi Dier
Executive Vice President/General Counsel
Karah Parschauer
Executive Vice President
Camille Bedrosian
Executive Vice President
Erik Harris
Executive Vice President
Dennis Huang
Executive Vice President
Thomas Kassberg
Executive Vice President
John Pinion
Director
Corazon Sanders
Independent Director
William Aliski
Independent Director
Deborah Dunsire
Independent Director
Lars Ekman
Independent Director
Matthew Fust
Independent Director
Michael Narachi
Independent Director
Shehnaaz Suliman
No Data
  • All
  • Financials
  • Insiders
More
About RARE
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.

Webull offers kinds of Ultragenyx Pharmaceutical Inc stock information, including NASDAQ:RARE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RARE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RARE stock methods without spending real money on the virtual paper trading platform.